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Symposium Articles
From Bench to Society: Law and Ethics at the
Frontier of Genomic Technology
*

Jamie S. King

On February 8, 2013, the UCSF/UC Hastings Consortium on Law,
Science, and Health Policy and the Hastings Law Journal co-sponsored a
symposium titled From Bench to Society: Law and Ethics at the Frontier
of Genomic Technology. The impetus behind this conference was to
bring together leading national scholars trained in genetics, genetic
counseling, medicine, law, philosophy, psychology, sociology, ethics, and
public policy to spend the day examining the vast potential implications
(both good and bad) of the next wave of major advances in genetic and
genomic testing for patients, providers, their families, the practice of
medicine, and society as a whole. We hoped to inspire the group to think
collectively about what we can do now to glean all of the potential
benefits we can from spectacular scientific achievements, such as whole
genome sequencing, whole exome sequencing, and epigenetics, while
simultaneously implementing safeguards to protect individuals and
society from the challenges that lay ahead. The day was quite eyeopening for audience members and panelists alike, and fostered
numerous discussions and potential collaboration opportunities during
breaks and the end of the day reception.
The day began with an introduction to genetics and genomics by
Professor Kelly Ormond, who provided the non-scientists in the room
with a wonderful overview of everything from the basics of genetic
science to recent developments in sequencing and targeted sequencing
analysis. Professor Ormond’s presentation set the stage for subsequent
discussions.
We then moved into our first of three substantive panels, titled
*
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Predictions of Future Health, which I moderated. This panel posed
significant questions regarding the potential benefits and detriments of
using whole genome sequencing to make predictions of future health
states. Dr. Wylie Burke focused her presentation on the expansive set of
information available through whole genome sequencing and the
challenges of communicating that information to individuals. She also
argued, as do she and her colleagues Susan Brown Trinidad and Ellen
Wright Clayton in their Article in this issue, Seeking Genomic
Knowledge: The Case for Clinical Restraint, that health care providers
should only focus on genetic information that has sufficient clinical utility
to guide medical decisions. This proposal would open the door to private
companies that offer personal genetic information directly to consumers
regarding a large portion of the human genome that so far reveals little
actionable clinical information. Next, Dr. Mildred Cho presented
evidence on how the implementation of genomics in clinical practice is
being driven by forces other than the clinical judgment of clinicians.
Further, her presentation explored the role that insurance, lack of
comprehensive regulatory policy, commercialization, and particularly,
intellectual property policy play in determining the use of genomic
advances. Finally, Professor Mark Rothstein acknowledged that for
symptomatic or high risk individuals, whole genome sequencing is a
marvelous advance in diagnostic testing. He then argued his lecture titled
The Case Against Precipitous, Population-Wide Whole Genome
Sequencing, which explored the significant challenges associated with
whole genome sequencing for asymptomatic individuals, including a lack
of clinical utility, lack of available genetic counselors to help translate the
data to patients, and a general lack of societal understanding of the
implications of many genetic findings. This panel raised many questions
regarding what information should be returned to individuals as a result
of genetic sequencing. Many of these issues are addressed in the Article
Return of Results in Genetic Testing: Who Owes What to Whom, When
and Why? by Stephanie Alessi.
After lunch, Dr. George Poste gave the keynote address titled
Personalized (Precision) Medicine: Science, Law and Health Policy. Dr.
Poste’s presentation provided a whirlwind view of the technological
potential to offer precision medical care designed for individual patients,
including the use of personal handheld mobile devices to gather and
communicate health data to providers on a regular basis. He also noted
the significant privacy, economic, regulatory, and translational challenges
that access to both genomic information and the technological capability
to provide that information to individuals will create. Dr. Poste’s keynote
spurred many questions and much discussion regarding how best to
address patient demand and offer clinically relevant information.

King_9 (B. Buchwalter) (Do Not Delete)

August 2013]

FROM BENCH TO SOCIETY

9/25/2013 12:17 PM

103

Following the keynote address, Professor Osagie Obasogie
moderated our second substantive panel titled Individualized Medicine.
Dr. Robert Nussbaum discussed the scientific and clinical challenges that
exist in today’s relatively unregulated and privatized world of genetic and
genomic research. Like Dr. Cho, he noted that the commercialization of
clinical research and treatment has led to substantial inefficiencies in the
system, including an inability to identify prior cases of rare genetic
diseases. He argued for improved regulation of genetic tests and greater
public access to genetic data. Next, Dr. Barbara Koenig gave a very
interesting presentation from the perspective of an anthropologist
examining the growth of the commercial genomic industry in the last few
years, and the societal forces that have contributed to that growth. She
argued that critical examination of genomics and its role in society is
needed to properly address the societal changes that access to this
technology portends. Finally, Professor Hank Greely examined the wide
range of challenges that arise with personalized genomics, specifically the
challenge associated with creating computer programs to analyze the
genome and translate the sequence into meaningful information for
patients. Professor Greely proposed the creation of an entity to
continuously and simultaneously curate the medical literature and
interpret both genetic variations to disease risk and the strength of the
findings. This information could then be published on the Internet,
subject to peer review and open comment. Such a tool could be used to
continually update all clinicians and researchers with information on the
relevance of certain genotypes.
Our final panel of the day, moderated by Professor David Faigman,
examined recent advances in behavioral genetics and its potential for use
in legal settings. This panel was conducted in a Fred Friendly format,
which gave all of our panelists, Professor Josh Buckholtz, Professor
Deborah Denno, Professor Nita Farahany, and Dr. Taylor Smith the
opportunity to answer all questions posed by Professor Faigman and the
audience. This panel was the most lively of the day, and Professors
Buckholtz, Denno, and Farahany engaged in a fascinating debate
regarding the usefulness of behavioral genetics research and individual
genotypes in criminal sentencing. Describing the use of genetics in
criminal courts for mitigation purposes, Professor Farahany noted that it
had not been very compelling. Professor Denno argued in favor of
permitting genetics information that has been associated with certain
behaviors to be used in death penalty sentencing. Her article in this issue
critiques a study recently published in Science by Aspinwall, Brown, and
Tabery titled The Double-Edged Sword: Does Biomechanism Increase or
Decrease Judges’ Sentencing of Psychopaths? Further, Dr. Smith
discussed the role of epigenetics in psychological and behavioral
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disorders, and he and his coauthors, Matthew Maccani and Valerie
Knopik, explore the use of epigenetic research in a legal and policy
context in their Article in this issue titled Maternal Smoking During
Pregnancy and Offspring Health Outcomes: The Role of Epigenetic
Research in Informing Legal Policy and Practice.
Overall, the day proved fascinating though daunting on many fronts.
I invite you to view the conference on the UCSF/UC Hastings
consortium webpage, as this brief introduction cannot begin to do it
justice. The opportunities that we, as a society, will have to explore our
genetic information, to have a better understanding of the role our
genetics plays in the development of disease, and in some cases, behavior
are unbounded. However, significant challenges will arise regarding how
we analyze, translate, understand, and protect this information. A
general consensus appeared to exist that genomic technology is coming
at a pace that far exceeds our ability to address these challenges and that
as a society, we are largely unprepared for its arrival. However, through
interdisciplinary symposia like this one, we can improve our
understanding of the implications of advances in genomics and ignite
further discussions and collaborations on how to best handle the
individual and societal risks associated with some of our greatest
scientific achievements.

